Airly Raises $3.3 M from Marquee Tech Investors

March 22, 2021

Airly notes it raised a $3.3m funding round to scale its AI-powered air quality platform globally. Founded in 2016, Airly is a cleantech startup that provides ultra-local, accurate, predictive air quality data to help tackle air pollution globally. Airly enables governments, companies, and individuals to reduce air pollution globally.

Airly’s customers comprise over 600 local governments and cities including Hong Kong, Jakarta, Oslo, Granada, corporates such as Philips, Virgin, Innogy, PwC, Veolia and Skanska. Airly will open offices in the UK and US as it doubles staff count.

The funding round was led by firstminute capital, an early-stage venture fund based in London, which is led by Brent Hoberman CBE and backed by over 70 unicorn tech founders. Leading angel investors also participated, including: Uber founder Garrett Camp via Expa, Bolt CEO Markus Villig, founding Editor-in-Chief of WIRED David Rowan, Pipedrive founder Ragnar Sass and Ferry Heilemann, co-founder of Leaders for Climate Action. Previous investors, including Sir Richard Branson Family Office and Henkel board member Konstantin von Unger who also participated in the round. Existing investors include Giant Ventures and Sir Ronald Cohen’s family.

Airly provides actionable insights about air quality with its AI-driven algorithms that predict air pollution for the next 24 hours with a verifiability of up to 95%. Airly gives customers across the globe an environmental intelligence platform by installing networks of sensors that track all the key pollution markers – particulate matter (PM1, PM2.5, PM10) and gases (NO2, O3, SO2 and CO). Airly’s R&D department is also partnering with mobility companies to roll out sensor-equipped cars & scooters to track air quality with even higher resolution.

More than 10 million people die each year from air pollution, according to a new study — far more than the number of people who will ever die from Covid-19. Exposure to air pollution increases the risk of stroke, dementia, heart disease, lung cancer and chronic respiratory diseases, with children particularly vulnerable. Recent research by Airly shows a high correlation between airborne particulate matter and deaths per capita related to Covid-19. The first person in the world to have air pollution exposure listed as a cause of fatality on her death certificate was announced in December 2020, when nine-year-old Ella Adoo-Kissi-Debrah died as a result of acute respiratory failure, severe asthma, and exposure to air pollution.

Airly CEO and co-founder Wiktor Warchałowski commented: “Polluted air is a plague on our health – it’s like a pandemic in slow motion. Improving air quality needs to be at the core of the world’s post-pandemic rebuild and Airly is the first step to pollution-free cities. With this funding, we can expand our global footprint to support even more cities, enterprises, and communities to repair the air and empower them with data and actionable insights.”

With 62% of the world’s governments sharing no real-time air quality data, Airly provides accurate, ultra-local, predictive data for governments, media, and businesses to tackle the issue of air pollution head-on. Airly’s platform acts as a warning system for pollution at street level and in real-time with greater accuracy and at a lower cost for cities & enterprises.

firstminute capital Co-Founder and Executive Chairman Brent Hoberman said: “With public and political awareness of the air quality crisis reaching a tipping point – from California fires to the landmark cause of death case in London – air quality data will become a key utility for consumers, companies, and policymakers. Thanks to their technology, which is orders of magnitude less expensive than incumbent solutions, Airly provides greater density and 95% accurate AI-driven prediction. At firstminute capital – we believe that the company has the potential to become a single source of truth for air quality globally.”

In addition to improving its environmental intelligence platform and algorithms, Airly will use the money to expand its team with the addition of sales, marketing and engineering talents in several countries. The company will approximately double its current 35-person staff by the end of 2021.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version